Hugel Inc. Achieves Strong Q3 Financial Results
Hugel Inc., a leading name in the global medical aesthetics industry, has recently reported substantial financial outcomes for the third quarter. The company recorded impressive net sales amounting to KRW105.9 billion, showcasing its robust growth trajectory.
Profitability Highlights
In this quarter, Hugel's operating profit reached KRW47.4 billion, while the net income was registered at KRW38 billion. With these results, the company demonstrated a solid gross profit margin of 77%, reinforcing its position as a financially sound player in the market.
Global Market Expansion
The significant sales success can be attributed to the effective global distribution of its primary products, botulinum toxin and hyaluronic acid dermal fillers. These categories have sparked demand in major international markets, further accentuated by the company’s efforts to penetrate the global aesthetics market.
Contribution from Major Markets
Exports have been a pivotal factor, comprising approximately 80% of the net sales from botulinum toxin and fillers. The growth rate for overseas sales in these categories surged by around 11% year-on-year, reaching KRW72.6 billion. Notably, sales from the largest aesthetic markets significantly contributed to overall performance.
Product Category Performance
By segment, botulinum toxin, branded as Letybo, generated KRW60.2 billion in the third quarter, while the hyaluronic acid dermal fillers, marketed as Revolax internationally, contributed KRW30.2 billion. Additionally, the cosmetics brands WELLAGE and BYRYZN BR demonstrated remarkable potential, achieving KRW14.9 billion in quarterly net sales—a 65% increase compared to the previous year.
CEO Insights on Future Prospects
“We are thrilled with the robust sales growth, particularly in critical regions such as the US, China, Europe, and Brazil. We anticipate these markets will continue to be a significant growth driver for our business,” expressed Carrie Strom, the President and Global CEO of Hugel.
About Hugel
Founded in 2001, Hugel has emerged as a global leader within the medical aesthetics field, focusing on the development of injectables that enhance skin rejuvenation. Their product lineup includes botulinum toxin, hyaluronic acid fillers, and skin boosters. The company is dedicated to ensuring high standards of safety and quality while fostering advancements through educational initiatives.
Global Presence and Continuity
Over the last two decades, Hugel has successfully established operations in around 70 countries, supported by nine global subsidiaries sprawled across various markets. This extensive reach provides Hugel with a firm standing to leverage ongoing industry growth and expand its market influence.
Contact Information
For more information, please contact:
Jihyun Kim, Manager of the PR Team, Hugel
jihyun.kim@hugel-inc.com
Frequently Asked Questions
What were Hugel's Q3 net sales?
The company's net sales in Q3 reached KRW105.9 billion.
How much did Hugel earn in operating profit this quarter?
Hugel reported an operating profit of KRW47.4 billion for Q3.
What percentage of sales came from international markets?
Approximately 80% of sales from botulinum toxin and fillers came from exports.
Which products contributed significantly to Hugel's revenue?
Botulinum toxin (Letybo) and hyaluronic acid fillers (Revolax) were key revenue contributors.
How long has Hugel been in operation?
Hugel has been in operation since 2001, marking over two decades in the medical aesthetics industry.
